Legend Biotech (LEGN) Cash & Equivalents (2019 - 2025)

Legend Biotech (LEGN) has 7 years of Cash & Equivalents data on file, last reported at $286.7 million in Q4 2025.

• In Q4 2025, Cash & Equivalents changed 0.0% year-over-year to $286.7 million; the TTM figure through Dec 2025 stood at $286.7 million (changed 0.0% YoY), while the FY2025 annual figure was $286.7 million, changed 0.0% from the prior year.
• Cash & Equivalents climbed to $286.7 million in Q4 2025, from $278.9 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $1.3 billion in Q4 2023 and bottomed at $201.3 million in Q2 2024.
• A 5-year average of $593.0 million and a median of $457.5 million in 2021 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2021 — Cash & Equivalents soared 446.63% — and 2024, when it tumbled 83.68%.
• Year by year, Cash & Equivalents stood at $688.9 million in 2021, then climbed by 14.09% to $786.0 million in 2022, then surged by 62.55% to $1.3 billion in 2023, then slumped by 77.56% to $286.7 million in 2024, then changed by 0.0% to $286.7 million in 2025.
• The last three Cash & Equivalents figures came in at $286.7 million (Q4 2025), $278.9 million (Q3 2025), and $266.6 million (Q2 2025), per Business Quant data.

Peer Comparison